Overview

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe and in the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of NN1250 (insulin degludec) in subjects with type 1 diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Insulin
Insulin Aspart
Insulin degludec, insulin aspart drug combination
Insulin Glargine
Insulin, Globin Zinc
Insulin, Long-Acting